What are the dosing guidelines for Invega (paliperidone) in adults with schizophrenia, including adjustments for renal impairment, elderly patients, orally disintegrating tablets, and the long‑acting injectable formulation?

Invega Dosing Guidelines

For adults with schizophrenia, start Invega (paliperidone) extended-release tablets at 6 mg once daily in the morning without titration, with a therapeutic range of 3-12 mg/day, and adjust dosing based on renal function—reducing to 3 mg initially (max 6 mg) for mild impairment or 1.5 mg initially (max 3 mg) for moderate-to-severe impairment. 1

Oral Extended-Release Tablets (INVEGA®)

Standard Adult Dosing for Schizophrenia

• Initial dose: 6 mg once daily (morning administration)
• Therapeutic range: 3-12 mg/day
• No titration required at initiation 1
• Dose adjustments: Only after clinical reassessment, with intervals >4 days between increases
• Increments: 3 mg/day when increasing 1
• Maximum dose: 12 mg/day

Administration Requirements

Critical: Tablets must be swallowed whole—never chewed, divided, or crushed 1. The medication uses a nonabsorbable shell that releases drug at a controlled rate; patients may see tablet shells in stool, which is normal and expected.

Food: Can be taken with or without food 1

Renal Impairment Adjustments

Dosing must be individualized based on creatinine clearance 1:

Mild impairment (CrCl 50-80 mL/min):

• Initial: 3 mg once daily
• Maximum: 6 mg once daily 1

Moderate-to-severe impairment (CrCl 10-50 mL/min):

• Initial: 1.5 mg once daily
• Maximum: 3 mg once daily 1

Severe impairment (CrCl <10 mL/min):

• Not recommended—no data available 1

This is a common pitfall: renal dosing adjustments are frequently overlooked in psychiatric settings, potentially leading to drug accumulation and toxicity 2.

Elderly Patients

Same dosing as younger adults if renal function is normal 1. However, because elderly patients commonly have diminished renal function, assess creatinine clearance and adjust accordingly using the renal impairment guidelines above. For elderly with moderate-to-severe renal impairment, the maximum dose is 3 mg once daily 1.

Hepatic Impairment

• Mild-to-moderate (Child-Pugh A and B): No adjustment needed 1
• Severe: Not studied—use with caution

Schizoaffective Disorder Dosing

• Standard dose: 6 mg once daily (morning)
• Range: 3-12 mg/day
• No initial titration required
• Same adjustment principles apply 1

Long-Acting Injectable Formulations

Once-Monthly Paliperidone Palmitate (PP1M)

Initiation regimen 3, 4:

• Day 1: 150 mg eq. (234 mg) deltoid injection
• Day 8: 100 mg eq. (156 mg) deltoid injection
• No oral supplementation needed

Needle selection for deltoid:

• <90 kg: 1-inch, 23-gauge needle
• ≥90 kg: 1.5-inch, 22-gauge needle 3

Maintenance dosing:

• Range: 25-150 mg eq. (39-234 mg)
• Recommended: 75 mg eq. (117 mg) monthly
• Site: Deltoid (weight-adjusted needle) or gluteal (1.5-inch, 22-gauge regardless of weight)
• Flexibility: Day 8 dose ±2 days; monthly doses ±7 days 3, 4

Renal adjustments for PP1M:

• Mild impairment (CrCl 50-80 mL/min): 25% dose reduction 5

Three-Month Paliperidone Palmitate (PP3M)

Eligibility: Only switch after ≥4 months of stable PP1M treatment 5

Conversion: First PP3M dose = 3.5× the last PP1M dose 5:

• PP1M 50 mg → PP3M 175 mg
• PP1M 75 mg → PP3M 263 mg
• PP1M 100 mg → PP3M 350 mg
• PP1M 150 mg → PP3M 525 mg

Timing: Give at the time of next scheduled PP1M injection (±1 week window) 5

Subsequent dosing: Every 3 months (±2 weeks) 5

Important caveat: The lowest PP3M starting dose (175 mg) is associated with higher discontinuation risk—consider starting at higher doses when clinically appropriate 6

Six-Month Paliperidone Palmitate (PP6M)

Real-world data shows PP6M is initiated after extensive prior LAI experience (average 21.9 months on PP1M and 27.8 months on PP3M) 7. Patients transition directly from PP1M (32.5%) or PP3M (67.5%), with 66% starting at the higher 1560 mg dose strength 7.

Switching from Other Antipsychotics

From oral antipsychotics: Initiate paliperidone palmitate the day after discontinuing oral treatment 3, 4

From other LAIs (including long-acting risperidone): Start paliperidone palmitate at the time of the next scheduled injection of the previous LAI 3, 4

Critical warning: Do not coadminister with risperidone—paliperidone is risperidone's major active metabolite, creating additive exposure risk 1

Clinical Outcomes by Formulation

Adherence and outcomes improve with longer dosing intervals 7:

• 6-month adherence: PP1M 59.4%, PP3M 75.8%, PP6M 100%
• 12-month adherence: PP1M 51.4%, PP3M 59.1%, PP6M 73.9%
• Schizophrenia-related hospitalizations at 3 months: PP1M 5.1%, PP3M 2.1%, PP6M 1.8%

This evidence supports the 2025 INTEGRATE guidelines' emphasis on individualized treatment based on patient preferences regarding route of administration and the 2020 APA recommendation for LAIs in patients with adherence concerns 8, 9.

Key Pitfalls to Avoid

1. Crushing/splitting tablets: Destroys controlled-release mechanism
2. Ignoring renal function: Particularly in elderly—always calculate CrCl 2
3. Premature PP3M switching: Must have ≥4 months PP1M stability first 5
4. Risperidone coadministration: Creates dangerous additive paliperidone exposure 1
5. Starting PP3M at 175 mg: Associated with higher discontinuation 6